---
schema_version: "secwatch.filing_event.v1"
accession: "0001388658-26-000070"
form_type: "8-K"
ticker: "IRTC"
cik: "0001388658"
company_name: "iRhythm Holdings, Inc."
filed_at: "2026-08-06T20:15:12+00:00"
generated_at: "2026-08-06T20:19:20.653508+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# iRhythm Q2 revenue $224M (+20% YoY), raises guidance; acquires VitalConnect for $287.5M

## Summary
- Revenue $224.2M (+20.1% YoY); net loss $0.4M vs $14.2M loss; adjusted EBITDA $43.3M (19.3% margin).
- FY2026 revenue guidance raised to $880-890M; adjusted EBITDA margin 13-14%.
- Acquiring VitalConnect for ~$287.5M ($237.5M cash + $50M stock); expected close by end of 2026.
- Settled Baxter patent litigation with $50M payment; cross-license and 6-year covenant not to sue.
- FDA cleared third-gen algorithm; expected to cut clinician review time ~50% and save $100M over 5 years.

## SEC filing metadata
- accession: 0001388658-26-000070
- form_type: 8-K
- ticker: IRTC
- cik: 0001388658
- company_name: iRhythm Holdings, Inc.
- filed_at: 2026-08-06T20:15:12+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1388658/000138865826000070/0001388658-26-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1388658/000138865826000070/irtc-20260731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001388658-26-000070
- JSON: https://secwatch.observer/filing/0001388658-26-000070.json
- Plain text: https://secwatch.observer/filing/0001388658-26-000070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.